Axe Compute

Axe Compute Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Axe Compute (AGPU) as of Nov 4, 2026 is 4.27 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 97.99 % — a change of -95.64% (lower).

Cash Conversion

4.27 %

YoY

-95.64%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Axe Compute is 2025 4.27 % . Cash Conversion Rate (OCF/Net Income) of Axe Compute was 2024 97.99 % . It decreases by -95.64% lower compared to the previous year.

The Axe Compute Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
52.43 USD
Jan 1, 2019
45.03 USD
Jan 1, 2020
47.36 USD
Jan 1, 2021
62.11 USD
Jan 1, 2022
48.07 USD
Jan 1, 2023
94.32 USD
Jan 1, 2024
97.99 USD
Jan 1, 2025
4.27 USD
The Axe Compute Cash Conversion history
YEARCash ConversionYoY
4.27 %-95.64%
97.99 %+3.89%
94.32 %+96.23%
48.07 %-22.61%
62.11 %+31.15%
47.36 %+5.16%
45.03 %-14.10%
52.43 %-29.43%
74.29 %+10.66%
67.14 %-57.04%
156.29 %+216.79%
49.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axe Compute Stock analysis

What does Axe Compute do? Predictive Oncology, Inc. generates revenue through its subsidiaries Helomics Holding Corporation and Skyline Medical Inc. Helomics applies artificial intelligence to patient tumor data to personalize cancer therapies and develop new-targeted therapies, offering CLIA-certified clinical testing for oncologists. Skyline Medical Inc. markets the STREAMWAY System, which automates medical fluid disposal, targeting hospitals and clinics globally. The company's products serve healthcare providers seeking advanced diagnostic and waste management solutions. Helomics focuses on personalized cancer treatment decisions using AI-driven analysis, while Skyline Medical Inc. provides automated fluid disposal systems. The STREAMWAY System is sold through domestic and international divisions to medical facilities requiring efficient waste handling. TumorGenesis Inc. supports laboratory-based tumor research, complementing Helomics' clinical offerings. The company's revenue streams include AI-based therapy personalization services and the STREAMWAY System sales. Healthcare providers, including oncologists and medical facilities, purchase these products to enhance treatment precision and operational efficiency. Subsidiaries operate under the parent company's structure, with Helomics handling AI applications and Skyline Medical managing medical device distribution. Axe Compute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Axe Compute stock

Cash Conversion Rate (OCF/Net Income) of Axe Compute is 4.27 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Axe Compute changed from 97.99 % to 4.27 %, representing a -95.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Axe Compute since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Axe Compute with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Axe Compute

All Key Metrics — Axe Compute